siRNA drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (21)
Papers in which this entity is mentioned.
- Single-cell exon deletion profiling reveals splicing events that shape gene expression and cell state dynamics. (2026)
- FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy. (2025)
- Tumour-wide RNA splicing aberrations generate actionable public neoantigens. (2025)
- Towards understandings of serine/arginine-rich splicing factors. (2023)
- Genetic compensation triggered by mutant mRNA degradation. (2019)
- Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways. (2019)
- OncoKB: A Precision Oncology Knowledge Base. (2017)
- Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. (2017)
- A role for human homologous recombination factors in suppressing microhomology-mediated end joining. (2016)
- The cell cycle regulator CCDC6 is a key target of RNA-binding protein EWS. (2015)
- EWS and FUS bind a subset of transcribed genes encoding proteins enriched in RNA regulatory functions. (2015)
- BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. (2015)
- Position-specific binding of FUS to nascent RNA regulates mRNA length. (2015)
- MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. (2014)
- PVT1 dependence in cancer with MYC copy-number increase. (2014)
- Mitogen-activated protein kinase modulates ethanol inhibition of cell adhesion mediated by the L1 neural cell adhesion molecule. (2013)
- RNA splicing: a new player in the DNA damage response. (2013)
- ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. (2012)
- Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. (2011)
- ViennaRNA Package 2.0. (2011)
- Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. (2009)
Merged raw entities (5)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| sirna | drug | 46 | 107 |
| small interfering rna | drug | 4 | 6 |
| ctbp2 targeted sirna | drug | — | — |
| sirna-silenced | drug | — | — |
| tbc1d5 sirna | drug | — | — |